Market Overview

Feltl: Saba's 3Q12 Preliminary Results Strong


In a research report published this morning by Feltl & Company, Saba Software's (NASDAQ: SABA) billings remain impressive.

According to Feltl, “Saba reports preliminary 3Q12 results; SaaS billings remain impressive. Saba reported preliminary components to its 3Q12 results. Full 3Q12 results will not be available until the company files its 10-Q upon completion of an internal accounting review. Preliminary results versus our estimates: Total revenue of $32M vs. our $33.1M estimate; Non-GAAP EPS of ($0.04) vs our ($0.04) estimate; Cloud billings growth 63% Y/Y vs. our 37% estimate. We believe this implies total SaaS billings of $18.5M vs. our $15.6M estimate; Cloud revenues growth 56% Y/Y vs. our 67% estimate. We believe this implies Cloud revenues of $13.7M vs. our $11.4M estimate; Cloud deferred revenues grew 102% Y/Y vs. our 78% Y/Y estimate. We believe this implies Cloud deferred revenues of $31.8M vs. our $28.0M estimate.”

Feltl maintains its Buy rating and $16 PT on Saba Software, which is currently trading at $10.25.

Posted-In: Feltl & Co.Analyst Color Reiteration Analyst Ratings


Related Articles (SABA)

View Comments and Join the Discussion!

Latest Ratings

CBBMorgan StanleyUpgrades10.0
GDCredit SuisseDowngrades184.0
GEOJP MorganDowngrades26.0
TRUERBC CapitalDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Brean Murray Carret Lowers PT to $37 on InterMune

UPDATE: Brean Murray Carret Downgrades Allos Therapeutics to Hold